The development of anti-angiogenic heparan sulfate oligosaccharides

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Angiogenesis targeting with vascular endothelial growth factor (VEGF) inhibitors improves progression-free survival but offers modest overall survival benefits in cancer therapy.
• Resistance to VEGF inhibitors can arise from alternative angiogenic cytokines like fibroblast growth factor 2 (FGF2), interleukin 8 (IL-8), and stromal-cell-derived factor 1α (SDF-1α).
• Many angiogenic cytokines, including VEGF-A, FGF2, IL-8, and SDF-1α, require heparan sulfate (HS) for their biological activity.

Purpose of the Study:

• To explore heparan sulfate (HS) as a novel target for anti-angiogenic cancer therapy.
• To investigate the potential of targeting multiple angiogenic cytokines simultaneously using HS mimetics.
• To demonstrate the feasibility of creating synthetic HS fragments with biological activity against angiogenic cytokines.

Main Methods:

• Review of clinical trials on VEGF inhibitors and anti-angiogenic therapies.
• Analysis of the role of various angiogenic cytokines (FGF2, IL-8, SDF-1α) in resistance to VEGF inhibition.
• Investigation into the dependence of angiogenic cytokines on heparan sulfate (HS) for activity.
• Development and testing of synthetic heparan sulfate (HS) fragments.

Main Results:

• Heparan sulfate (HS) is essential for the activity of multiple key angiogenic cytokines implicated in cancer.
• Targeting HS presents an opportunity to overcome resistance to current anti-angiogenic therapies.
• Synthetic HS fragments of defined structure have been successfully generated and shown to possess biological activity.

Conclusions:

• Heparan sulfate (HS) is a promising target for developing novel anti-angiogenic cancer therapies.
• Synthetic HS mimetics offer a strategy to inhibit tumor angiogenesis by targeting multiple cytokines.
• This approach holds potential for more effective cancer treatment by overcoming resistance mechanisms.